Overview

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Status:
Completed
Trial end date:
2021-10-06
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to severe atopic dermatitis (AD) Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation To continue to assess the safety and tolerability throughout the study
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal